November 18, 2013 / 9:51 PM / 4 years ago

BRIEF-Pfizer gets FDA Approval for additional use of Xeljanz in Rheumatoid Arthritis

Nov 18 (Reuters) - Pfizer : * Announces FDA approval of supplemental application to expand xeljanz

(tofacitinib citrate) labeling to include additional patient-reported

outcomes data for adults with moderately to severely active rheumatoid

arthritis * Source text for Eikon * Further company coverage

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below